Cargando…

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)

Background: In people with overweight/obesity and type 2 diabetes (T2D), achievement of weight loss can be a challenge. STEP 2 investigated the efficacy and safety of semaglutide 2.4 mg for weight management in adults with overweight/obesity and T2D. Methods: This randomized, double-blind, double-du...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahman, Syed Kasfur, Davies, Melanie, Færch, Louise, Jeppesen, Ole K, Pakseresht, Arash, Pedersen, Sue D, Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A, Lingvay, Ildiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Abstracts … Esicon 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067799/ http://dx.doi.org/10.4103/2230-8210.342311

Ejemplares similares

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D
por: Kunder, Sushil, et al.
Publicado: (2022)

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial
por: Prakash, Prashanth S, et al.
Publicado: (2022)

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D
por: Manjunath, Aparna, et al.
Publicado: (2022)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
por: Kumar, K B Sharan, et al.
Publicado: (2022)

Abstract 141: CGM-based measurements for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-treated patients with type 2 diabetes: A post hoc analysis
por: Chandrappa, Manu, et al.
Publicado: (2022)

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program
por: Srivastava, Kunal, et al.
Publicado: (2022)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
por: Perreault, Leigh, et al.
Publicado: (2022)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Abstract 124: Study of lipid profile pattern in type 2 diabetes
por: Hegde, Sakinya, et al.
Publicado: (2022)

Abstract 110: Prevalence of asymptomatic bacteriuria in patients with type 2 diabetes mellitus
por: Kolli, Sumanas Gopal Datta, et al.
Publicado: (2022)

Abstract 35: A study on serum irisin levels in type 2 diabetes mellitus
por: Gumpina, Srinivas Susheel
Publicado: (2022)

Abstract 52: Clinical efficacy of dapagliflozin in patients with newly diagnosed type 2 diabetes
por: Patil, Surekha Mahesh
Publicado: (2022)

Abstract 11: Should all subjects with Type 2 diabetes mellitus receive magnesium supplementation
por: Talwar, Vipan, et al.
Publicado: (2022)

Abstract 130: Association between asymptomatic bacteriuria and serum Vitamin D in patients with type 2 diabetes
por: Nabi, Tauseef, et al.
Publicado: (2022)

Abstract 142: Endocrine neoplasia type 2B with a rare mutation: A case report
por: Garg, Umesh Kumar, et al.
Publicado: (2022)

Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
Publicado: (2022)

Abstract 88: Prevalence of holotranscobalamin deficiency among vegetarian and nonvegetarian patients with type 2 diabetes mellitus using metformin
por: Bonny, Lavanya, et al.
Publicado: (2022)

Abstract 120: Prevalence of hypogonadism in men with type 2 diabetes mellitus and its association with insulin resistance, metabolic and clinical parameters
por: Singh, Jaspreet, et al.
Publicado: (2022)

Abstract 137: Improved glycemic control among people with type 2 diabetes with a digital therapeutics approach in collaboration with clinicians
por: Singal, Arbinder, et al.
Publicado: (2022)

Abstract 127: Pituitary resistance to thyroid hormone due to a novel mutation in the NCOR2 gene: The first case report
por: Shukla, Ajay, et al.
Publicado: (2022)

Abstract 4: Derived time-in-range is associated with major adverse cardiovascular event in T2D: Data from the DEVOTE trial
por: Pathan, Muzammil Khan A, et al.
Publicado: (2022)

Abstract 119: Management of newly diagnosed type 2 diabetes mellitus with HBA1C > 10% in patients reluctant to take insulin
por: Panikar, Krish, et al.
Publicado: (2022)

Abstract 148: Preoperative determinants of length of stay in people with type 2 diabetes mellitus undergoing an elective CABG: An observational single centre study
por: Fatema, Zareen, et al.
Publicado: (2022)

Abstract 131: Evaluation of left ventricular systolic function using global longitudinal strain by 2D speckle tracking echocardiography in patients with acromegaly
por: Singh, Nameirakpam Dhanachand, et al.
Publicado: (2022)

Abstract 136: Video-based supervised exercise intervention successfully improves fitness in people with Type 2 diabetes: Outcomes from Diabefly(®) digital therapeutics platform
por: Singal, Arbinder, et al.
Publicado: (2022)

Abstract 140: Significant reduction in HbA1c levels among participants with poorly controlled type 2 diabetes on diabefly(®) digital therapeutics program using multidisciplinary approach
por: Singal, Chitra Selvan Arbinder, et al.
Publicado: (2022)

Abstract 2: Effectiveness and safety of early growth hormone treatment in children born small for gestational age: Long-term data from NordiNet® International Outcome Study (IOS) and ANSWER program
por: Ranjan, K M, et al.
Publicado: (2022)

Abstract 28: Change in glycaemic parameters in adults with type 2 diabetes initiated with or switched to insulin degludec/insulin aspart (IDegAsp) in a real-world setting – An analysis of Indian cohort of ARISE study
por: Baruah, Manash P, et al.
Publicado: (2022)

Abstract 62: Relative contribution of insulin resistance and beta cell dysfunction in subjects with metabolic syndrome and new onset diabetes, as assessed by HOMA 2: A comparative analysis from a South Indian cohort
Publicado: (2022)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_733lrtcpf8mfur0i5pv1873fl9